STOCK TITAN

Alvotech Ordinary Shares - ALVO STOCK NEWS

Welcome to our dedicated page for Alvotech Ordinary Shares news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech Ordinary Shares stock.

Alvotech (NASDAQ: ALVO) is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar medicines aimed at enhancing patient access to affordable treatments worldwide. Established in 2013, the company has committed itself to becoming a leader in biogenerics, focusing on the creation of cost-effective biosimilars that meet stringent quality standards. Alvotech operates through a fully integrated model, addressing every step from cell line development to commercial manufacturing.

Alvotech's headquarters in Reykjavik, Iceland hosts a state-of-the-art flexible manufacturing facility that underscores the company's commitment to high-quality and efficient production. The company's portfolio includes biosimilars for autoimmune disorders, eye conditions, osteoporosis, respiratory diseases, and cancer. Alvotech has successfully launched two biosimilars and is actively working on nine more candidates.

In recent developments, Alvotech announced positive top-line results for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and has received FDA approval for AVT04, a biosimilar to Stelara®. The company is also advancing in its U.S. strategic partnership with Teva Pharmaceuticals for the high-concentration interchangeable biosimilar to Humira®, marketed under Quallent’s private label. Financially, Alvotech reported increased revenues of $37 million in Q1 2024 and strengthened its position with a strategic refinancing transaction led by GoldenTree Asset Management, enhancing its financial flexibility and reducing upcoming debt maturities.

Alvotech's global reach is bolstered by strategic commercial partnerships with renowned pharmaceutical companies like Teva, STADA Arzneimittel AG, Fuji Pharma Co., Ltd., and many others. These collaborations extend across the United States, Europe, Japan, China, and several other regions, leveraging local expertise to provide expansive market access.

For more information on Alvotech and to stay updated with the latest news, visit www.alvotech.com.

Rhea-AI Summary
Alvotech and Bioventure announce approval of AVT02 biosimilar in Egypt, increasing patient access to more affordable biologics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
Alvotech to release financial results for H1 2023 on August 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Teva Pharmaceuticals and Alvotech have expanded their strategic partnership agreement, with Teva acquiring subordinated convertible bonds from Alvotech. The partners are focused on obtaining FDA approval for AVT02, a biosimilar candidate for Humira. The agreement includes exclusive commercialization rights for Teva in the U.S. for two new biosimilar candidates and line extensions of two current biosimilar candidates. Teva will provide financial support and increased involvement in manufacturing and quality at Alvotech's facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.51%
Tags
none
Rhea-AI Summary
Alvotech to participate in Jefferies Healthcare Conference on June 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
conferences

FAQ

What is the current stock price of Alvotech Ordinary Shares (ALVO)?

The current stock price of Alvotech Ordinary Shares (ALVO) is $11.91 as of December 20, 2024.

What is the market cap of Alvotech Ordinary Shares (ALVO)?

The market cap of Alvotech Ordinary Shares (ALVO) is approximately 3.7B.

What does Alvotech specialize in?

Alvotech specializes in the development and manufacturing of high-quality biosimilar medicines aimed at making treatments more affordable and accessible globally.

Where is Alvotech headquartered?

Alvotech is headquartered in Reykjavik, Iceland.

What are some recent achievements of Alvotech?

Recently, Alvotech announced positive top-line results for its AVT05 biosimilar and received FDA approval for AVT04, a biosimilar to Stelara. The company also secured a strategic refinancing transaction led by GoldenTree Asset Management.

Who are Alvotech's key commercial partners?

Alvotech's key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd., and Cipla among others, extending its market reach across the U.S., Europe, Japan, China, and more.

How does Alvotech ensure high-quality production?

Alvotech ensures high-quality production through its state-of-the-art flexible manufacturing facility located in Reykjavik, Iceland, and a fully integrated model addressing every step from cell line development to commercial manufacturing.

What is the financial outlook for Alvotech in 2024?

Alvotech has raised its revenue guidance for 2024 to $400-$500 million and tightened its guidance for EBITDA to $100-$150 million, driven by rapid progress in commercialization and development.

What are biosimilars?

Biosimilars are biologic medical products highly similar to already approved reference products, offering comparable quality, safety, and efficacy at a lower cost.

What diseases do Alvotech's biosimilars target?

Alvotech's biosimilars target autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and various cancers.

How does Alvotech contribute to global healthcare?

Alvotech contributes to global healthcare by developing cost-effective biosimilar medicines, increasing access to life-altering therapies, and forming strategic partnerships to maximize global reach.

Where can I find more information about Alvotech's investor relations?

More information about Alvotech's investor relations can be found on their investor portal at https://investors.alvotech.com.

Alvotech Ordinary Shares

Nasdaq:ALVO

ALVO Rankings

ALVO Stock Data

3.65B
104.58M
64.01%
6.04%
0.03%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Luxembourg City